Automated Detection of Psychedelic-Induced Head-Twitch Response in Mice

Jaster, Alaina M; González-Maeso, Javier

doi:10.1007/978-1-0716-3307-6_6

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…e.g. − Notably, Halberstadt et al have demonstrated that a significant correlation exists between the mouse HTR and the results of published drug discrimination studies with serotonergic hallucinogens using rats trained to discriminate either DOM or LSD from vehicle; a large number of agents was examined including DOM, DOET, DOB, and R (−)DOI. Given the reduced cost and labor associated with the HTR using mice relative to drug discrimination studies with rats, the former will probably see increased application in the future.…”

Section: Unconditioned Behaviormentioning

confidence: 99%

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents – A Review

Glennon,

Dukat

2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI, or DOX where X = −I) was first synthesized in 1973 in a structure–activity study to explore the effect of various aryl substituents on the then newly identified, and subsequently controlled, hallucinogenic agent 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM, or DOX where X = −CH3). Over time, DOI was found to be a serotonin (5-HT) receptor agonist using various peripheral 5-HT receptor tissue assays and later, following the identification of multiple families of central 5-HT receptors, an agonist at 5-HT2 serotonin receptors in rat and, then, human brain. Today, classical hallucinogens, currently referred to as serotonergic psychedelic agents, are receiving considerable attention for their potential therapeutic application in various neuropsychiatric disorders including treatment-resistant depression. Here, we review, for the first time, the historical and current developments that led to DOI becoming a unique, perhaps a landmark, agent in 5-HT2 receptor research.

show abstract